Saphnelo (anifrolumab) is a medication used with other medicines to treat patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Saphnelo (anifrolumab) is a first-in-class type I interferon receptor antibody with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.[1]
It is available in vial form, each containing 300 mg/2 mL (150 mg/mL) anifrolumab.[1]
Reviews
There are no reviews yet.